<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01572753</url>
  </required_header>
  <id_info>
    <org_study_id>NN9924-3794</org_study_id>
    <secondary_id>2010-019653-17</secondary_id>
    <secondary_id>U1111-1120-6776</secondary_id>
    <nct_id>NCT01572753</nct_id>
  </id_info>
  <brief_title>Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects</brief_title>
  <official_title>A Single Centre, Multiple Dose, Open Label Randomised Trial to Evaluate the Effect of Post Dose Meal Timings and the Effect of Volume of Water With Dosing on the Pharmacokinetic Properties of Oral Semaglutide in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of the trial is to evaluate the optimal dosing
      conditions for semaglutide (a long acting GLP-1 analogue) in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2012</start_date>
  <completion_date type="Actual">September 8, 2012</completion_date>
  <primary_completion_date type="Actual">September 8, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-24h; Area under the semaglutide concentration curve from time 0-24 hours after the 10th dosing</measure>
    <time_frame>0-24hrs after the 10th dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax; The maximum plasma semaglutide concentration</measure>
    <time_frame>Post-dose at day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax; Time to maximum plasma semaglutide concentration</measure>
    <time_frame>Post-dose at day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2; the terminal half-life of semaglutide</measure>
    <time_frame>Post-dose at day 10</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Post-dose fasting 120 mins/50 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 60 mins/50 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 30 mins/50 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 15 mins/50 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 120 mins/120 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 60 mins/120 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 30 mins/120 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-dose fasting 15 mins/120 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 120 mins/50 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 60 mins/50 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 30 mins/50 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 15 mins/50 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 120 mins/120 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 60 mins/120 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 30 mins/120 ml water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.</description>
    <arm_group_label>Post-dose fasting 15 mins/120 ml water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good general health as judged by the investigator, based on medical history, physical
             examination, electrocardiogram (ECG), vital signs and clinical laboratory

          -  Body mass index (BMI) of 18.5-30.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Males who are sexually active and not surgically sterilised, who or whose partner(s):
             a. are not using adequate contraceptive methods (e.g. condom with spermicidal
             foam/gel/film/cream or contraceptives with a Pearl Index below 1%, such as implants,
             injectables, combined oral contraceptives, or hormonal intrauterine devices or
             diaphragm + spermicide) or b. do not refrain from sexual intercourse during the trial
             and until 30 days following the last dose of trial medication. In addition, subjects
             must not donate sperm for the duration of the trial and for 30 days following the last
             dose of trial medication or c. sterilization of either partner

          -  Suffer from a life threatening disease or has a history of any clinically significant
             disease or disorder

          -  History of acute idiopathic or chronic pancreatitis

          -  Calcitonin value equal to or above 50 ng/L

          -  Any clinically significant abnormal laboratory test results (haematology, biochemistry
             and urinalysis), as judged by the investigator and any of the following laboratory
             safety results (based on screening results): Amylase, lipase and creatinine, above
             upper normal range. Aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT)
             and gamma-glutamyl-transpeptidase (gamma-GT) above 1.5 times upper normal range (UNR).
             Thrombocytes below 0.75 times lower normal range (LNR) or above 1.25 times UNR.
             Leucocytes outside 3.0 to 11.0x10^9/L (normal range is 3.91 to 8.77x10^9/L. Sodium
             outside the range 130.0 to 150.0 mmol/L (normal range is 136-145 mmol/L). Potassium
             outside the range 3.0 to 5.5 mmol/L (normal range is 3.5 to 5.1 mmol/L)

          -  Any clinically significant abnormal ECG, as judged by the investigator

          -  Subjects who are smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2012</study_first_submitted>
  <study_first_submitted_qc>April 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2012</study_first_posted>
  <last_update_submitted>February 23, 2017</last_update_submitted>
  <last_update_submitted_qc>February 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

